

## Instructions to Authors 2014

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

*Tables.* Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios  
 International Institute of Anticancer Research (IIAR)  
 Editorial Office of ANTICANCER RESEARCH,  
 IN VIVO, CANCER GENOMICS and PROTEOMICS.  
 1st km Kapandritiou-Kalamou Road  
 P.O. Box 22, GR-19014 Kapandriti, Attiki  
 GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.



# 9th INTERNATIONAL CONFERENCE OF ANTICANCER RESEARCH

6-10 October 2014,  
Porto Carras, Sithonia, Greece

[www.iiar-anticancer.org](http://www.iiar-anticancer.org)

## Information

### Under the auspices of:

- The Union for International Cancer Control (UICC)
- The Asian and Pacific Federation of Clinical Biochemistry (APFCB)
- The Asian Pacific Organization for Cancer Prevention (APOCP)
- The Austrian Society for Radiation Oncology (ÖGRO)
- The European Group on Tumor Markers (EGTM)
- The Hungarian Society of Epidemiology
- The International Geriatric Radiotherapy Group (IGRG)
- The International Institute of Anticancer Research (IIAR)
- The International Society for Biological and Environmental Repositories (ISBER)
- The International Society of Oncology and Biomarkers (ISOBM)
- The Italian Society of Uro-Oncology (SIUrO)
- The Latinamerican and Caribbean Society of Medical Oncology (SLACOM)
- The Lithuanian Society of Radiation Oncology (LSRT)
- The North-Eastern German Society of Gynecological Oncology (NOGGO)
- The Polish Society of Radiation Oncology (PSTRO)
- The Portuguese Society of Radiotherapy - Oncology (SPRO)
- The Society of Biotherapeutic Approaches, Japan
- The Szeged Foundation for Cancer Research, Hungary
- The Turkish Society for Electron Microscopy (TSEM)

### Supported by:

- The International Institute of Anticancer Research



**Deadline for Registration:** September 26, 2014.

**Deadline for submission of abstracts:** August 10, 2014.

### Dates and Venue

The 9th International Conference of Anticancer Research will be held at the Porto Carras Grand Resort, Sithonia, Halkidiki, Greece, from 6 to 10 October, 2014.

### General Policy

The purpose of the Anticancer Research Conferences is to exchange scientific information worldwide and to discuss recent advances in both broad and specialized areas of experimental and clinical cancer research. International Scientific and Medical Societies are invited to participate in the Conference by organizing specialized sessions. This

initiative presents a forum for inter-Society communication allowing the organization and coordination of international activities on cancer. Special sessions will be devoted to the discussion and arrangement of international cooperation projects and activities, encompassing the aims of the International Institute of Anticancer Research.

The Conference is organized and supported by the International Institute of Anticancer Research.

The Scientific Program will comprise of oral (10, 15, 30 or 40 minutes) and poster presentations. Both overviews and original works will be presented. Each oral presentation will be allocated a five-minute discussion-time. Six conference rooms will be used simultaneously. Posters will be exhibited for 1-2 days. Projection facilities for PowerPoint presentations will be provided.

## Organizing Committee

- P.A. Abrahamsson**, Malmö, Sweden  
**N. Agnantis**, Ioannina, Greece  
**F.E. Ahmed**, Greenville, NC, USA  
**C. Alexiou**, Erlangen, Germany  
**L. Amaral**, Lisbon, Portugal  
**F.L. Ampil**, Shreveport, LA, USA  
**R. Andersson**, Lund, Sweden  
**S. Arbak**, Istanbul, Turkey  
**V. Barak**, Jerusalem, Israel  
**D.-T. Bau**, Taichung, Taiwan  
**G. Bauer**, Freiburg, Germany  
**A. Bishayee**, Signal Hill, CA, USA  
**R. Bjerkvig**, Bergen, Norway  
**G. Broich**, Monza, Italy  
**C. Carlberg**, Kuopio, Finland  
**J. Carlsson**, Uppsala, Sweden  
**D. Characiejus**, Vilnius, Lithuania  
**C.J. Chen**, Taipei, Taiwan  
**G. Ciarimboli**, Münster, Germany  
**B.F.C. Clark**, Aarhus, Denmark  
**R. Clarke**, Washington, DC, USA  
**P. Collery**, Bastia, France  
**H. Cross**, Vienna, Austria  
**M. De Braekeleer**, Brest, France  
**K. De Meirleir**, Brussels, Belgium  
**A.Z. Dudek**, Chicago, IL, USA  
**A. Dutour**, Lyon, France  
**P. Dziegiel**, Wrocław, Poland  
**T. Efferth**, Mainz, Germany  
**W. Engström**, Uppsala, Sweden  
**M. Eskelinen**, Kuopio, Finland  
**J.A. Fernandez-Pol**, Chesterfield, MO, USA  
**A. Fields**, Jacksonville, FL, USA  
**M. Friedrich**, Krefeld, Germany  
**R. Friedrich**, Hamburg, Germany  
**H.-J. Gabius**, Munich, Germany  
**R. Ganapathi**, Charlotte, NC, USA  
**A.F. Gazdar**, Dallas, TX, USA  
**V. Gebbia**, Palermo, Italy  
**J.W. Greiner**, Bethesda, MD, USA  
**F. Guadagni**, Rome, Italy  
**C. Hastie**, Guildford, Surrey, UK  
**J. Hau**, Copenhagen, Denmark  
**R. Hoffman**, San Diego, CA, USA  
**S. Holdenrieder**, Bonn, Germany  
**T. Isbir**, Istanbul, Turkey  
**S. Jhanwar**, New York, NY, USA  
**M. Jhanwar-Uniyal**, New York, NY, USA  
**B. Kaina**, Mainz, Germany  
**E. Kandil**, New Orleans, LA, USA  
**D.G. Kieback**, Riesa (Dresden), Germany  
**I. Kiss**, Pécs, Hungary  
**R. Klapdor**, Hamburg, Germany  
**R. Knecht**, Hamburg, Germany  
**M. Kohonen-Corish**, Sydney, NSW, Australia  
**M. Koutsilieris**, Athens, Greece  
**K. Kubota**, Mibu, Tochigi, Japan  
**S. Kumar**, Manchester, UK  
**P.M. Kumar**, Manchester, UK  
**O.D. Laerum**, Bergen, Norway  
**S.A. Lamprecht**, Beer-Sheva, Israel  
**W. Lichtenegger**, Berlin, Germany  
**D. Lincoln**, Chapel Hill, QLD, Australia  
**B. Littlefield**, Andover, MA, USA  
**F. Lumachi**, Padova, Italy  
**S. Mitra**, Galveston, TX, USA  
**R. Molina**, Barcelona, Spain  
**J. Molnár**, Szeged, Hungary  
**N. Motohashi**, Tokyo, Japan  
**R.M. Nagler**, Haifa, Israel  
**N. Nguyen**, Tucson, AZ, USA  
**C. Nicolini**, Genova, Italy  
**C. Pace-Asciak**, Toronto, ON, Canada  
**S. Pathak**, Houston, TX, USA  
**G.J. Pilkington**, Portsmouth, UK  
**C.D. Platsoucas**, Norfolk, VA, USA  
**A. Polliack**, Jerusalem, Israel  
**J. Reichrath**, Homburg/Saar, Germany  
**D.A. Ribeiro**, Santos, SP, Brazil  
**M. Rigaud**, Limoges, France  
**F.M. Robertson**, Houston, TX, USA  
**M. Roselli**, Rome, Italy  
**G.R. Rutteman**, Utrecht, Netherlands  
**C. Sansom**, London, UK  
**S. Sarkar**, Boston, MA, USA  
**A. Schauer**, Göttingen, Germany  
**D. Schiffer**, Vercelli, Italy  
**J. Schneider**, Alcorcón (Madrid) Spain  
**M. Schneider**, Wuppertal, Germany  
**O.J. Semmes**, Norfolk, VA, USA  
**A. Seth**, Toronto, ON, Canada  
**G. Sica**, Rome, Italy  
**J. Slansky**, Denver, CO, USA  
**K. Smetana**, Prague, Czech Republic  
**S.S. Smith**, Duarte, CA, USA  
**R.M. Snapka**, Columbus, OH, USA  
**J. Sterling**, Nashville, TN, USA  
**T. Stigbrand**, Umeå, Sweden  
**K. Syrjänen**, Helsinki, Finland  
**R.T. Todorova**, Sofia, Bulgaria  
**O. Topolcan**, Pilsen, Czech Republic  
**G.C. Torre**, Finale Ligure (SV), Italy  
**V. Treska**, Pilsen, Czech Republic  
**M. de L.G. Trigo**, Porto, Portugal  
**G. Tsangaris**, Athens, Greece  
**E. Vairaktaris**, Athens, Greece  
**D. Vesely**, Tampa, FL, USA  
**D. Vetvicka**, Prague, Czech Republic  
**J.K. Vishwanatha**, Fort Worth, TX, USA  
**G. Vollmer**, Dresden, Germany  
**A. Wani**, Columbus, OH, USA  
**Y. Yen**, Duarte, CA, USA  
**C.H. Yip**, Petaling Jaya, Malaysia  
**O. Zoras**, Heraklion, Greece

## Scientific Program

### *Experimental Research Sessions*

1. Oncogenes; tumor suppressor genes; growth factors; signal transduction.
2. Molecular and cellular biology of cancer.
3. Cancer stem cells.
4. Cancer cell differentiation.
5. Cancer genomics. Microarray technology.
6. Cancer proteomics.
7. Cancer systems biology and signaling.
8. Cancer metabolism and autophagy.
9. Reactive oxygen/nitrogen species and cancer.
10. MicroRNAs in cancer.
11. Invasion and metastasis.
12. Cytogenetics and genetics.
13. Epigenetics.
14. Tumor angiogenesis and anti-angiogenesis.
15. Multi-drug and drug resistance. Mechanisms and reversal.

16. Apoptosis.
17. Tumor microenvironment; cell-cell interactions; adhesion; stroma; cancer-associated fibroblasts.
18. Carcinogenesis. Viral oncogenesis.
19. New anticancer agents.
20. Natural production in cancer drug development.
21. Experimental chemotherapy.
22. Immunobiology of cancer.
23. Gene therapy.
24. Aging and cancer.

### *Clinical Research Sessions*

25. Diagnosis and prognosis of cancer.
26. Cancer surgery.
27. Serum markers.
28. Clinical chemotherapy.
29. Immunotherapy; biotherapy; vaccines.
30. Hormone therapy.
31. Radiotherapy.
32. Hyperthermia.
33. Personalized medicine in cancer.
34. Advances in breast cancer.
35. Advances in gynecological cancer.
36. Advances in prostate cancer.
37. Advances in neurooncology.
38. Advances in colorectal cancer.
39. Advances in head and neck cancer.
40. Advances in gastrointestinal cancer.
41. Advances in hemato-oncology.
42. Melanoma: New therapies and biomarkers.
43. Chemoprevention. Environmental exposure and cancer risk.
44. Epidemiology.
45. Nutrition and cancer. Nutritional aspects of cancer prevention.
46. Special symposia.

## Publications

Abstracts of all contributed papers will be published in a special issue of ANTICANCER RESEARCH, which will be distributed to registrants during the Conference, as well as to all subscribing libraries and indexing services (print and online through the Stanford University HighWire Press). After recommendation by the Organizing Committee, selected contributions will be invited as complete original papers or reviews to be submitted for publication in ANTICANCER RESEARCH. Paper submissions will also be welcome during the Conference.

Abstracts (titles and authors) will be announced in [www.iia-anticancer.org](http://www.iia-anticancer.org) upon acceptance. The final conference program will be publicised on September 10, 2014.

## Registration

- **Registration is required of all participants.**
- **Registration deadline:** 26 September, 2014.
- **Deadline for submission of abstracts:** 10 August, 2014.
- **Registration fee:** EURO 260.00; Students, EURO 140.00; accompanying person, EURO 100.00 (each); Children, no fee.
- The registration fee for the Conference participants partially covers: attendance at the scientific sessions; all Conference material and documentation (final program, list of participants, book of Abstracts, Conference folder, Certificate of attendance and registration badge) from the Conference Secretariat; participation in all social events (social dinners, guitar recital, coffee breaks, closing gala dinner), and conference gifts.
- The registration fee for accompanying persons covers: participation in all social events; eligibility for special accommodation fees (the same offer that apply to Conference participants).
- Registration will be regarded as final only after all forms and registration plus accommodation fees have been received by the Editorial Office of Anticancer Research.

## Accommodation

Hotel reservation requests should be submitted directly to the Editorial Office of Anticancer Research. The Porto Carras Grand Resort (★★★★★) is located in a beautiful, peaceful setting by the sea and will provide excellent service and quality half-board accommodation for all participants.

- Accommodation fees:
  - Double room: EURO 66.00 per person, per day.
  - Single room: EURO 98.00 per person, per day.
  - Children 2-12 years old as 3rd person in double room: EURO 35.00.
- The fee covers: accommodation in A (★★★★★) type rooms (bath, balcony, radio, TV, telephone), breakfast, dinner and transportation from and to the Airport of Thessaloniki on October 5 and October 11, 2014, respectively.
- Service hours: Breakfast (buffet): 7.30 – 10.00 a.m.; Dinner (formal club style) 19.00 – 22.30 p.m.; Self-service restaurant for lunch: 12.30 – 14.00 p.m.
- Accommodation requests are valid if made through the official conference Registration Form. For accommodation & registration to be secured all fees need to have been paid in advance.
- Cancellations: Abstract and registration plus accommodation fees will be returned if participation is cancelled before August 10, 2014. No refunds will be offered past this date.

## Travel Arrangements

The Conference will officially commence on the morning of October 6, 2014. Therefore, participants should preferably arrive on October 5, 2014. The conference will conclude with the closing gala dinner on October 6, 2014. Participants are advised to finalize their travel plans at the earliest possible date. Details of date, flight number and time of arrival at Thessaloniki Airport should be given to the Editorial Office not later than September 26, 2014.

Aegean Airlines: [www.aegeanair.com](http://www.aegeanair.com)

Olympic Airways: [www.olympicairlines.com](http://www.olympicairlines.com)

## Airport – Hotel Transportation

Shuttle buses will provide transportation from Thessaloniki Airport to the Hotel only on Sunday, October 5, 2014, and from the Hotel to the airport only on Saturday, October 11, 2014. Participants will be welcomed at the airport by a conference representative. Participants arriving on days other than October 5 or departing on days other than October 11 will have to hire a taxi (50 min, Euro ~12) at their own expense.

## Weather

October is a very pleasant month in Sithonia, Greece. The average temperature is 24°C (range 20-30°C).

## Instructions for Submitting an Abstract

1. Only abstracts containing new results (original research work or overviews) will be accepted. Abstracts should clearly and adequately describe the objectives and results of the research. All abstracts must be submitted in English.
2. All abstracts need to be accompanied by a completed Conference Registration Form made out in the name of the Author presenting the paper.
  - a. Each abstract should include a title (in capital letters), names of all authors (with the name of the author who will be presenting the paper underlined), as well as complete address(es).
  - b. Two types of abstracts may be submitted:
    - Short abstract, not exceeding 300 words.
    - Long abstracts not exceeding 1500 words, with 1-2 figures or tables (max size 8 cm width x 12 cm height), including abstract, introduction, materials and methods, results, discussion, acknowledgements, references.
  - c. Careful typing and proof-reading are essential.
  - d. Abstract forms will not be provided.
3. Abstracts and a completed Conference Registration Form should be sent to: Dr. John G. Delinasios, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd, P.O. Box 22, Kapandriti 19014, Greece. E-mail: [journals@iia-anticancer.org](mailto:journals@iia-anticancer.org).

### Abstracts must arrive at our offices

**by August 10, 2014, at the latest.**

4. A reply (regarding decision, acceptance or revision) will reach the author within 5-12 days from submission.

## Instructions for Poster Presentations

Abstracts scheduled for presentation in poster sessions will be grouped by topic, numbered and listed in the program, and published in the Abstract Book, as well as in ANTICANCER RESEARCH. Posters will be exhibited for 1-2 days and program listings will specify the time for poster discussion.

The original abstract of each poster presentation should arrive by August 10, 2014, at the latest at our offices. For the preparation of the abstract, please follow the Instructions for Submitting an Abstract.

The poster board surface area is 0.64 m<sup>2</sup> [0.8 m (31.5 inches) high and 0.8 m (31.5 inches) wide]. Poster presentations should include: title, authors, institutional affiliation, abstract, short introduction, methods, results, discussion, references and conclusion.



Porto Carras, Sithonia, Greece

# 9th INTERNATIONAL CONFERENCE OF ANTICANCER RESEARCH

6-10 October 2014, Porto Carras, Sithonia, Greece

## CONFERENCE REGISTRATION FORM

- Please reserve my place at the 9th International Conference of Anticancer Research.
- I shall be accompanied by ..... adults and ..... children.  
(Please complete separate forms for each accompanying person.)
- I plan to present ..... poster(s). Topic number .....
- I plan to present ..... oral communication(s): ..... minutes. Topic Number .....
- Abstract is attached. (Please follow the instructions for submitting an abstract).
- I shall require accommodation in single  or double  room;  
Accommodation fees: Double room, EURO 66.00 per person per night; Single room, EURO 98.00 per person per night;  
Children 2-12 years old, as 3rd person in the same room, EURO 35.00.  
The fee covers accommodation in 5\*-type rooms, breakfast, dinner, transportation from and to Thessaloniki Airport.  
Registration fee: EURO 260.00; Students, EURO 100.00; Accompanying person, EURO 100.00.
- Registration fee is enclosed. Accommodation fee for ..... nights is also enclosed.  
(Cheques should be made payable to Delinasios G.J. & CO G.P., Athens, Greece. Credit cards are NOT accepted.)
- Please send an invoice for EURO ..... (and instructions for payment).
- I am a student (certificate enclosed).
- I will require transportation between Thessaloniki Airport and the Porto Carras Hotels on October 5 and 11, 2014.  
Time of my arrival: ..... Flight no.: .....  
Time of my departure: ..... Flight no.: .....
- Please enter my personal subscription to Anticancer Research/IN VIVO/2015 (including all previous volumes online) at the special conference rate.  online (EURO 200.00);  print & online (EURO 300.00).

---

Title: .....

Name: ..... Sex: male  or female

Institution (or Company): .....

Address: .....

Tel: ..... Fax: ..... E-mail: .....

---

**Deadline for registration: September 26, 2014.**

**Deadline for submission of abstracts: 10 August, 2014.**

Please mail completed form and Registration & Accommodation fees to:

Dr. John G. Delinasios, International Institute of Anticancer Research,  
1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti 19014, Greece.

Tel. / Fax : +30 22950 53389; e-mail: [iiar@iiar-anticancer.org](mailto:iiar@iiar-anticancer.org). Website: [www.iiar-anticancer.org](http://www.iiar-anticancer.org)

Please photocopy for additional forms.

Skin Test Protocol for the Prevention of Hypersensitivity Reactions to Oxaliplatin. M. PAGANI, P. BONADONNA ( <i>Mantova; Verona, Italy</i> ) .....	537
Combinations of Platinums and Selected Phytochemicals as a Means of Overcoming Resistance in Ovarian Cancer. F. HUQ, J.Q. YU, P. BEALE, C. CHAN, L. ARZUMAN, M.U. NESSA, M.E.H. MAZUMDER ( <i>Sydney; Concord, NSW, Australia</i> ) .....	541
* Short Review; Membrane Transporters as Mediators of Cisplatin Side-effects. G. CIARIMBOLI ( <i>Münster, Germany</i> ) .....	547
9th International Conference of Anticancer Research, 6-10 October 2014, Porto Carras, Sithonia, Greece. Information.	
* Reviews (pages 423, 435, 443, 455, 465, 471, 477, 483, 487, 547)	

Preface: Platinum and Other Heavy Metal Coordinating Compounds in Cancer Chemotherapy: Overview of Verona ISPCX XI. F. MUGGIA, R. LEONE, A. BONETTI ( <i>New York, NY, USA; Verona, Legnago, Italy</i> ).	
Biography of Professor Barnett Rosenberg: A Tribute to His Life and His Achievements. J.D. HOESCHELE ( <i>Ypsilanti, MI, USA</i> ) .....	417
* Review: Targeted Agents and Oxaliplatin-containing Regimens for the Treatment of Colon Cancer. A. BONETTI, J. GIULIANI, F. MUGGIA ( <i>Legnago, Italy; New York, NY, USA</i> ) .....	423
* Review: Predictive Role of Repair Enzymes in the Efficacy of Cisplatin Combinations in Pancreatic and Lung Cancer. G.J. PETERS, A. AVAN, M. GALLEGOS-RUIZ, V. ORSINI, A. AVAN, E. GIOVANNETTI, E.F. SMIT ( <i>Amsterdam, Netherlands; Mashhad, Iran</i> ) .....	435
* Review: New Use of Metals as Nanosized Radioenhancers. A. POTTIER, E. BORGHI, L. LEVY ( <i>Paris, France</i> ) .....	443
* Review: Dicycloplatin, a Novel Platinum Analog in Chemotherapy: Synthesis of Chinese Pre-clinical and Clinical Profile and Emerging Mechanistic Studies. J.J. YU, X. YANG, Q. SONG, M.D. MUELLER, S.C. REMICK ( <i>Morgantown, WV, USA; Beijing/Jiang-Su, PR China</i> ) .....	455
* Review: Standardization of Chemotherapy and Individual Dosing of Platinum Compounds. F. PUISSET, A. SCHMITT, E. CHATELUT ( <i>Toulouse; Dijon, France</i> ) .....	465
* Review: Understanding and Improving Platinum Anticancer Drugs – Phenanthriplatin. T. C. JOHNSTONE, G.Y. PARK, S.J. LIPPARD ( <i>Cambridge, MA, USA</i> ) .....	471
* Review: From Platinum Compounds to Targeted Therapies in Advanced Thoracic Malignancies. M. JAKOPOVIC, A. THOMAS, A. LOPEZ-CHAVEZ ( <i>Zagreb, Croatia; Bethesda, MD; Portland, OR, USA</i> ) .....	477
* Short Review: Neuronal Drug Transporters in Platinum Drugs-induced Peripheral Neurotoxicity. G. CAVALETTI, C. CERESA, G. NICOLINI, P. MARMIROL ( <i>Monza, Italy</i> ) .....	483
* Review: Beyond Platinums: Gold Complexes as Anticancer Agents. C. NARDON, G. BOSCUCCI, D. FREGONA ( <i>Padova, Italy</i> ) .....	487
* Review: Platinum Drugs and DNA Repair Mechanisms in Lung Cancer. L. BONANNO, A. FAVARETTO, R. ROSELL ( <i>Padova, Italy; Barcelona, Spain</i> ) .....	493
Collateral Sensitivity to Cisplatin in KB-8-5-11 Drug-resistant Cancer Cells. B. DOHERTY, D. LAWLOR, J.-P. GILLET, M. GOTTESMAN, J.J. O’LEARY, B. STORDAL ( <i>Dublin, Ireland; Bethesda, MD, USA</i> ) .....	503
Antidepressants and Platinum Drugs. B.J. ENGELMANN, J.J. RYAN, N.P. FARRELL ( <i>Richmond, VA, USA</i> ) .....	509
Characterization of and Protection from Neurotoxicity Induced by Oxaliplatin, Bortezomib and Epothilone-B. C. CERESA, A. AVAN, E. GIOVANNETTI, A.A. GELDOF, A. AVAN, G. CAVALETTI, G.J. PETERS ( <i>Monza, Italy; Amsterdam, Netherlands; Mashhad, Iran</i> ) .....	517
How Liposomal Cisplatin Overcomes Chemoresistance in Ovarian Tumour Cells. D.P. STÖLTING, M. BORRMANN, M. KOCH, M. WIESE, H.-D. ROYER, G. BENDAS ( <i>Bonn; Düsseldorf, Germany</i> ) .....	525
Oxoglucine-Lanthanide Complexes: Synthesis, Crystal Structure and Cytotoxicity. Y.-C. LIU, Z.-F. CHEN, Y.-F. SHI, K.-B. HUANG, B. GENG, H. LIANG ( <i>Guilin, P.R. China</i> ) .....	531



Prognostic Value of Erythrocyte Sedimentation Rate and C-Reactive Protein in the Blood of Patients with Glioma. T. STROJNIK, T. ŠMIGOC, T.T. LAH ( <i>Maribor; Ljubljana, Slovenia</i> ) .....	339
Characteristics and Natural History of Patients with Colorectal Cancer Complicated by Infectious Endocarditis. Case Control Study of 25 Patients. M. OUAÏSSI, A.-S. STUDER, D. MEGE, F. THUNY, L. BOIRON, A. LOUNDOU, N. PIRRO, S. HAMED, C. FRASCONI, G. HABIB, P.-E. FOURNIER, F. COLLART, I. SIELEZNEFF, B. SASTRE ( <i>Marseille, France</i> ) .....	349
Long-term Statin Therapy Improves Oncological Outcome After Radical Gastrectomy for Stage II and III Gastric Cancer. D.H. NAM, HYUK LEE, J.C. PARK, S.K. SHIN, S.K. LEE, W.J. HYUNG, Y.C. LEE, M.W. KANG, S.H. NOH ( <i>Seoul, Republic of Korea</i> ) .....	355
Esophageal Stenosis: A Differential Diagnosis Between Esophageal Cancer and Metastasis from Other Neoplasia. I. PARIS, A. PRELAJ, C.E. ONESTI, A. BALDONI, M.R. GIOVAGNOLI, M. BASSANELLI, S. LAURO, P. MARCHETTI ( <i>Rome, Italy</i> ) .....	363
Over-Expression of the Overexpressed in Lung Cancer-1 Is Associated With Poor Prognosis in Colorectal Cancer. J. LIU, H. SONG, L. YAO, Y. LIU, Y. ZHANG, H. ZHAO, H. JI, Y. WANG ( <i>Harbin, P.R. China</i> ) .....	367
<b>Current Aspects and Future Direction in Gynaecological Oncology. 17-20 April 2013, Berlin, Germany - Selected Articles Presented at the 7th International Charité-Mayo Conference. Edited by J. Sehouli, W. Lichtenegger</b> .....	373-416
TNF- $\alpha$ 308 G/A Polymorphism and Cervical Intraepithelial Neoplasia. I.C. ROTAR, D. MUREȘAN, P. RADU, F. PETRIȘOR, S. APOSTOL, T. MARIANA, C. BUTUZA, F. STAMATIAN ( <i>Cluj Napoca, Romania</i> ) .....	373
Association Between Visceral Fat, IL-8 and Endometrial Cancer. R. CIORTEA, D. MIHU, C.M. MIHU ( <i>Cluj-Napoca, Romania</i> ) .....	379
Role of serum VEGFA, TIMP2, MMP2 and MMP9 in Monitoring Response to Adjuvant Radiochemotherapy in Patients with Primary Cervical Cancer – Results of a Companion Protocol of the Randomized NOGGO-AGO Phase III Clinical Trial. E.I. BRAICU, K. GASIMLI, R. RICHTER, M. NASSIR, S. KÜMMEL, J.-U. BLOHMER, I. YALCINKAYA, R. CHEKEROV, I. IGNAT, A. IONESCU, M. MENTZE, C. FOTOPOULOU, C. POP, W. LICHTENEGGER, J. SEHOULI, German North Eastern Society for Gynecological Oncology (NOGGO), Tumor Bank Ovarian Cancer (TOC) ( <i>Berlin; Essen, Germany; Cluj-Napoca, Romania</i> ) .....	385
ERCC1 Expression As a Predictor of Resistance to Platinum-based Chemotherapy in Primary Ovarian Cancer. M.Z. MUALLEM, I. BRAICU, M. NASSIR, R. RICHTER, J. SEHOULI, R. ARSENIC ( <i>Berlin, Germany</i> ) .....	393
ERCC1 Expression As a Predictive Marker of Cervical Cancer Treated with Cisplatin-based Chemoradiation. M.Z. MUALLEM, S. MARNITZ, R. RICHTER, C. KÖHLER, J. SEHOULI, R. ARSENIC ( <i>Berlin, Germany</i> ) .....	401
A Case of Primary Peritoneal Carcinoma: Evidence for a Precursor in the Fallopian Tube. S. NASSER, R. ARSENIC, P. LOHNEIS, P. KOSIAN, J. SEHOULI ( <i>Berlin, Germany</i> ) .....	407
The Role of Inhibitor of DNA-binding 1 (ID-1) Protein and Angiogenesis in Serous Ovarian Cancer. M.-P. KUBELAC, B. FETICA, I.-C. VLAD, A. FULOP, A. POPA, P. ACHIMAȘ-CADARIU ( <i>Cluj-Napoca, Romania; Berlin, Germany</i> ) .....	413
<b>Proceedings of the XI International Symposium of Platinum Coordination Compounds in Cancer Chemotherapy, 11-14 October 2012, Verona, Italy. Edited by F. Muggia, R. Leone, A. Bonetti</b> .....	417-550

Prognostic Significance of Ki-67 in Chemotherapy-naïve Breast Cancer Patients with 10-year Follow-up. H. NISHIMIYA, Y. KOSAKA, K. YAMASHITA, N. MINATANI, M. KIKUCHI, A. EMA, K. NAKAMURA, M. WARAYA, N. SENGOKU, H. TANINO, M. KURANAMI, W. MASAHICO ( <i>Sagamihara, Kanagawa, Japan</i> ) .....	259
Association Between Tumor Size and Immunohistochemical Expression of Ki-67, p53 and BCL2 in a Node-negative Breast Cancer Population Selected from a Breast Cancer Screening Program. A. GONZÁLEZ-SISTAL, A. BALTASAR SÁNCHEZ, C. DEL RIO, J.I. ARIAS, M. HERRANZ, Á. RUIBAL ( <i>Barcelona; A Coruña; Oviedo; Madrid, Spain</i> ) .....	269
Bevacizumab plus Weekly Paclitaxel With or Without Carboplatin for Previously-treated Non-squamous Non-Small Cell Lung Cancer. A. HATA, N. KATAKAMI, K. TANAKA, J. TAKESHITA, T. MATSUMOTO, K. MONDEN, K. NAGATA, K. MASAGO, R. KAJI, S. FUJITA, R. TACHIKAWA, K. OTSUKA, K. OTSUKA, K. TOMII ( <i>Kobe, Japan</i> ) .....	275
Effectiveness of FDG-PET in Screening of Synchronous Cancer of Other Organs in Patients with Esophageal Cancer. T. MIYAZAKI, M. SOHDA, T. HIGUCHI, N. TANAKA, S. SUZUKI, M. SAKAI, T. YOKOBORI, M. NAKAJIMA, M. FUKUCHI, Y. TSUSHIMA, H. KATO, H. KUWANO ( <i>Gunma; Tochigi, Japan</i> ) .....	283
Safety and Preliminary Efficacy of Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Localized Pancreatic Cancer. C. MÅNSSON, M. BERGENFELDT, R. BRAHMSTAEDT, B.-M. KARLSON, P. NYGREN, A. NILSSON ( <i>Uppsala; Lund, Sweden</i> ) .....	289
Zinc Supplementation Improves Anticancer Activity of Monocytes in Type-2 Diabetic Patients with Metabolic Syndrome. K. MEKSAWAN, U. SERMSRI, P. CHANVORACHOTE ( <i>Bangkok, Thailand</i> ) .....	295
Successful Use of Trastuzumab with Anthracycline-based Chemotherapy Followed by Trastuzumab Maintenance in Patients with Advanced HER2-positive Gastric Cancer. S. PALACIO, A. LOAIZA-BONILLA, M. KITTANEH, C. KYRIAKOPOULOS, R.E. OCHOA, M. ESCOBAR, B. ARANGO, M.H. RESTREPO, J.R. MERCHAN, C.M.S. ROCHA LIMA, P.J. HOSEIN ( <i>Miami, FL; Philadelphia, PA; Detroit, MI; Cleveland, OH, USA</i> ) .....	301
Latent Hypothyreosis as a Clinical Biomarker for Therapy Response Under Abiraterone Acetate Therapy. I. HEIDEGGER, U. NAGELE, A. PIRCHER, R. PICHLER, W. HORNINGER, J. BEKTIC ( <i>Innsbruck; Holl in Tyrol, Austria</i> ) .....	307
Predictive Scoring System Assessing the Need for Intraoperative Blood Transfusions During Hepatectomy for Hepatocellular Carcinoma. Y. YAMAMOTO, H. IKOMA, R. MORIMURA, H. KONISHI, Y. MURAYAMA, S. KOMATSU, A. SHIOZAKI, Y. KURIU, T. KUBOTA, M. NAKANISHI, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, C. SAKAKURA, T. OCHIAI, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	313
Complete Metabolic Remission with Gefitinib in a Hemodialysis Patient with Bone Metastases from Non-small Cell Lung Cancer. A. DEL CONTE, E. MINATEL, D. SCHINELLA, T. BAREVIC, S.M.M. BASSO, F. LUMACHI ( <i>Pordenone; Aviano; Padova, Italy</i> ) .....	319
Survival and Prognostic Factors in Children with Brain Tumors: Long-term Follow-up Single Center Study in Poland. M. POGORZALA, J. STYCZYNSKI, M. WYSOCKI ( <i>Bydgoszcz, Poland</i> ) .....	323
CA125 and HE4 levels in a Czech Female Population Diagnosed with Endometrial Cancer in Preoperative Management. J. PRESL, Z. NOVOTNY, O. TOPOLCAN, P. VLASAK, R. KUCERA, R. FUCHSOVA, J. VRZALOVA, L. BETINCOVA, S. SVOBODOVA ( <i>Pilsen; Prague, Czech Republic</i> ) .....	327
Adjuvant Radiotherapy for Stage III/IV Urothelial Carcinoma of the Upper Tract. E. JWA, Y.S. KIM, H. AHN, C.-S. KIM, J.-L. LEE, S.O. KIM, S.D. AHN ( <i>Seoul, Republic of Korea</i> ) .....	333

Detection of Lung Cancer by FDG-PET Cancer Screening Program: A Nationwide Japanese Survey. R. MINAMIMOTO, M. SENDA, S. JINNOUCHI, T. TERAUCHI, T. YOSHIDA, K. UNO, T. IINUMA, T. MURANO, R. NAKASHIMA, T. INOUE ( <i>Tokyo; Kobe; Kagoshima; Kurume; Chiba; Kumamoto; Yokohama, Japan</i> ).....	183
Usefulness of Monthly Chemotherapy for Patients with Unresectable Metastatic Colorectal Cancer. M. TOMODA, H. KAWAHARA, K. WATANABE, H. ENOMOTO, T. AKIBA, K. YANAGA ( <i>Chiba; Tokyo, Japan</i> ) .....	191
Prospective Phase II Trial of Second-line FOLFIRI in Patients with Advanced Colorectal Cancer Including Analysis of <i>UGT1A1</i> Polymorphisms: FLIGHT 2 Study. K. HIRATA, N. NAGATA, T. KATO, Y. OKUYAMA, H. ANDOH, K. TAKAHASHI, K. OBA, J. SAKAMOTO, S. HAZAMA, H. MISHIMA ( <i>Fukuoka; Kitakyushu; Hyogo; Kyoto; Akita; Aomori; Sapporo; Gifu; Yamaguchi; Aichi, Japan</i> ).....	195
Multimodal Treatment for T1-2 Supraglottic Cancer: The Impact of Tumor Location. G. SUZUKI, H. YAMAZAKI, E. OGO, T. ABE, N. HAYABUCHI, H. UMENO, T. NAKASHIMA, S. NAKAMURA, K. YOSHIDA ( <i>Kurume, Fukuoka; Kamigyo, Kyoto; Takatsuki, Osaka, Japan</i> ) .....	203
A Phase I Study of Concurrent Chemoradiotherapy Using Oral S-1 for Head and Neck Cancer. Y. FUJIMOTO, S. KATO, Y. ITOH, S. NAGANAWA, T. NAKASHIMA ( <i>Nagoya, Aichi, Japan</i> ) .....	209
Pemetrexed Combined with Platinum-based Chemotherapy for Advanced Malignant Peritoneal Mesothelioma: Retrospective Analysis of Six Cases. M. NAKANO, H. KUSABA, A. MAKIYAMA, H. ARIYAMA, S. ARITA, H. ODA, T. ESAKI, K. TAKAYOSHI, K. UCHINO, S. TAMURA, H. KUMAGAI, E. IWAMA, T. SHIRAKAWA, K. MITSUGI, S. TAKAISHI, K. AKASHI, E. BABA ( <i>Fukuoka, Japan</i> ) ...	215
Early Predictive Value of Non-response to Docetaxel in Neoadjuvant Chemotherapy in Breast Cancer Using <sup>18</sup> F-FDG-PET. T. HIRAKATA, Y. YANAGITA, T. FUJISAWA, T. FUJII, T. KINOSHITA, H. HORIKOSHI, N. OYA, T. AKIYOSHI, M. IJIMA, T. MIYAMOTO, H. KUWANO ( <i>Ota; Maebashi; Isesaki, Gunma, Japan</i> ) .....	221
Hypertension as a Predictive Marker for Bevacizumab in Metastatic Breast Cancer: Results from a Retrospective Matched-pair Analysis. S.P. GAMPENRIEDER, F. ROMEDER, C. MUß, M. PIRCHER, S. RESSLER, G. RINNERHALER, R. BARTSCH, C. SATTLBERGER, B. MLINERITSCH, R. GREIL ( <i>Salzburg; Vienna; Vöcklabruck, Austria</i> ) .....	227
Lack of Evidence for Predictive and Prognostic Value of Cyclin D1 Gene Polymorphism <i>CCND1</i> G870A for Oral Squamous Cell Carcinoma. A. ATAC, B. RIECKE, A.T. ASSAF, A. GRÖBE, R.E. FRIEDRICH, M. HEILAND, J.R. IZBICKI, L. KLUWE, M. BLESSMANN ( <i>Hamburg, Germany</i> ).....	235
Anaplastic Pelvic Carcinoma Secondary to Low-grade Endometrial Carcinoma. R. WATROWSKI, J. MÖCKEL, T. VENZKE, C. JÄGER, T. BAUKNECHT ( <i>Freiburg, Germany</i> ).....	239
Initial Experience with Oropharynx-targeted Radiation Therapy for Metastatic Squamous Cell Carcinoma of Unknown Primary of the Head and Neck. W.F. MOURAD, K.S. HU, D. SHASHA, C. CONCERT, D. ISHIHARA, W. LIN, R.A. SHOURBAJI, M. RYNIK, J.J. LUKENS, Z. LI, B.E. CULLINEY, A.S. KHORSANDI, T. TRAN, A. JACOBSON, S. MANOLIDIS, S. SCHANTZ, M. URKEN, M.S. PERSKY, L.B. HARRISON ( <i>New York, NY, U.S.A</i> ) .....	243
Is Endometrial Cancer Really a Neurophobic Tumor? A Case Report and Review of the Literature. M. NASSIR, A. ROTH, K. GASIMLI, E.I. BRAICU, C. FOTOPOULOU, C. MAWRIN, H. BADAHSHI, J.-P. WARNKE, J. SEHOULI ( <i>Berlin; Zwickau; Magdeburg, Germany; London, UK</i> ) .....	249

NOTCH4 Is a Potential Therapeutic Target for Triple-negative Breast Cancer. I. NAGAMATSU, H. ONISHI, S. MATSUSHITA, M. KUBO, M. KAI, A. IMAIZUMI, K. NAKANO, M. HATTORI, Y. ODA, M. TANAKA, M. KATANO ( <i>Fukuoka; Tokyo, Japan</i> ) .....	69
Modified Arabinoxylan from Rice Bran, MGN-3/Biobran, Sensitizes Metastatic Breast Cancer Cells to Paclitaxel <i>In Vitro</i> . M. GHONEUM, N.K. BADR EL-DIN, D.A. ALI, M. A. EL-DEIN ( <i>Los Angeles, CA, USA; Mansoura, Egypt</i> ) .....	81
The Therapeutic Potential of a Novel PSMA Antibody and its IL-2 Conjugate in Prostate Cancer. Y. SUGIMOTO, M. HIROTA, K. YOSHIKAWA, M. SUMITOMO, K. NAKAMURA, R. UEDA, R. NIWA, T. SUZAWA, M. YAMASAKI, K. SHITARA, T. KATO, K. NAKAMURA ( <i>Tokyo; Nagakute, Aichi; Takasaki, Gunma, Japan</i> ) .....	89
Hypersensitivity and Growth Adaptation of Oestrogen-deprived MCF-7 Human Breast Cancer Cells. P.D. DARBRE ( <i>Reading, UK</i> ) .....	99
ERCC1 Expression and Chemosensitivity in Uterine Cervical Adenocarcinoma Cells. Y. TORII, R. KATO, Y. MINAMI, K. HASEGAWA, T. FUJII, Y. UDAGAWA ( <i>Toyoake, Nagoya, Aichi; Tokyo; Tochigi, Japan</i> ) .....	107
A Novel Approach for Enriching Cancer Stem Cells from the Human SW-13 Adrenocortical Carcinoma Cell Line. W. ZENG, X. CHEN, Y. MA, Z. HUANG, Y. QIN, F. WU, L. WU, X. LIANG, Y. QIN, J. ZHOU, D. LU, X. KUANG, Q.Q. LI, Z. LUO ( <i>Nanning, PR China; Bethesda, MD, USA</i> ) .....	117
Pregnancy Stimulates Tumor Angiogenesis in Breast Carcinoma. A.-S. GENIN, M. ANTOINE, S. ARACTINGI, R. ROUZIER ( <i>Creteil; Paris; Versailles, France</i> ) .....	125
Demethylation of <i>RUNX3</i> by Vincristine in Colorectal Adenocarcinoma Cells. J.W. MOON, S.K. LEE, J.O. LEE, J.H. KIM, N. KIM, J. KIM, H.S. KIM, S.-H. PARK ( <i>Seoul, South Korea</i> ) .....	133
Active Hexose-correlated Compound Down-regulates HSP27 of Pancreatic Cancer Cells, and Helps the Cytotoxic Effect of Gemcitabine. S. SUENAGA, Y. KURAMITSU, S. KAINO, S.-I. MAEHARA, Y. MAEHARA, I. SAKAIDA, K. NAKAMURA ( <i>Ube, Yamaguchi; Fukuoka, Japan</i> ) .....	141
<i>Clinical Studies</i>	
Novel and Differential Accumulation of Mitochondrial DNA Deletions in Swedish and Vietnamese Patients with Colorectal Cancer. J. DIMBERG, T.T. HONG, M. SKARSTEDT, S. LÖFGREN, N. ZAR, A. MATUSSEK ( <i>Jönköping Sweden; Hanoi, Vietnam</i> ) .....	147
Touch Imprint Cytology of Core Needle Biopsy Specimens for the Breast and Quick Stain Procedure for Immediate Diagnosis. S. KEHL, C. MECHLER, S. MENTON, C. WEISS, S. WASGINDT, M. SÜTTERLIN, M. TRUNK ( <i>Mannheim; Erlangen; Tübingen, Germany</i> ) .....	153
Expression of Cytokeratin 20 Indicates Invasive Histological Phenotype in Poorly Differentiated Colorectal Adenocarcinoma. Y. IMAI, H. YAMAGISHI, K. FUKUDA, T. OKAMURA, Y. ONO, S. BAN, T. INOUE, Y. UEDA ( <i>Saitama; Tokyo, Japan</i> ) .....	159
Gene Expression Analysis Using a Highly Sensitive DNA Microarray for Colorectal Cancer Screening. Y. KOGA, N. YAMAZAKI, S. TAKIZAWA, J. KAWAUCHI, O. NOMURA, S. YAMAMOTO, N. SAITO, Y. KAKUGAWA, Y. OTAKE, M. MATSUMOTO, Y. MATSUMURA ( <i>Kashiwa; Kamakura; Tokyo, Japan</i> ) .....	169
Cytokeratin 7 as a Predictive Factor for Response to Concomitant Radiochemotherapy for Locally Advanced Cervical Cancer: A Preliminary Study. E. LAMBAUDIE, E. CHÉREAU, N. POUGET, J. THOMASSIN, M. MINSAT, E. CHARAFE-JAUFFRET, J. JACQUEMIER, G. HOUVENAEGHEL ( <i>Marseille, France</i> ) .....	177